Can a common MS drug help people with a rare nerve disease walk better?
NCT ID NCT06513533
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This clinical trial is testing whether dimethyl fumarate, a drug already used for multiple sclerosis, can improve balance and walking in adults with adrenomyeloneuropathy (AMN), a rare nerve disease. Forty participants will take either the drug or a placebo daily for 36 months, with regular clinic visits to measure motor function and safety. The goal is to see if the drug can ease motor problems and help understand the disease better.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dimethyl fumarate (also known as Skilarence or Tecfidera)
- What this could lead to
- If it works, this could point toward a treatment that improves balance and walking in people with adrenomyeloneuropathy.
- What could go wrong
- This is a mid-stage trial with only 40 participants, so results may not apply to everyone. The drug is already used for other conditions, but its effectiveness for this specific disease is unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENOMYELONEUROPATHY WITHOUT CEREBRAL INVOLVEMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bellvitge University Hospital
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Donostia University Hospital
Donostia / San Sebastian, Donostia, 20014, Spain
-
University Hospital 12 de Octubre
Madrid, Madrid, 28041, Spain